Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

Diffuse large B cell lymphoma (DLBCL) heterogeneity promotes recurrence and anti‐CD20‐based therapeutic resistance. Previous studies have shown that downregulation of MS4A1/CD20 expression after chemoimmunotherapy with rituximab leads to rituximab resistance. However, the mechanisms of CD20 loss rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Duanfeng, Mo, Qiuyu, Sun, Xiaoying, Wang, Xiaotao, Dong, Min, Zhang, Guozhen, Chen, Fangping, Zhao, Qiangqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409406/
https://www.ncbi.nlm.nih.gov/pubmed/34252986
http://dx.doi.org/10.1111/cas.15055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409406/
https://www.ncbi.nlm.nih.gov/pubmed/34252986
http://dx.doi.org/10.1111/cas.15055

Ejemplares similares